Ocular Therapeutix (OCUL) interim CFO discloses RSUs and stock options

Rhea-AI Filing Summary

Ocular Therapeutix, Inc. filed an initial ownership report for interim CFO Jason Shand Robins, detailing his equity holdings in the company as of January 20, 2026. He directly holds 52,656 shares of common stock, which include 20,917 unvested RSUs from a January 13, 2025 grant and 22,425 unvested RSUs from a January 2, 2026 grant. Each RSU represents one share of common stock and is scheduled to vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in equal yearly installments.

Robins also holds two stock option awards: one covering 110,600 shares of common stock at an exercise price of $8.12 per share, expiring on January 12, 2035, and another covering 68,195 shares at $11.82 per share, expiring on January 1, 2036. The first option, granted on January 13, 2025, vests over four years with 25% vesting on January 13, 2026 and the balance vesting monthly over the following three years. The second option, granted on January 2, 2026, vests over four years with 1/48 of the underlying shares vesting monthly starting one month after the grant date.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Robins Jason Shand

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

15 CROSBY DRIVE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/20/2026

3. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	52,656(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	01/12/2035	Common Stock	110,600	$8.12	D
Stock Option (Right to Buy)	(3)	01/01/2036	Common Stock	68,195	$11.82	D

Explanation of Responses:

1. Includes 20,917 restricted stock units ("RSUs") remaining unvested pursuant to an award of 31,375 RSUs granted under the 2019 Inducement Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation") on January 13, 2025, and 22,425 RSUs remaining unvested pursuant to an award of 22,425 RSUs granted under the Corporation's 2021 Stock Incentive Plan, as amended, on January 2, 2026. Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the respective date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.

2. This option was granted on January 13, 2025 and vests over four years, with 25% of the original number of shares vesting on January 13, 2026 and the remainder vesting in equal monthly installments over the three years after such date.

3. This option was granted on January 2, 2026 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date.

Remarks:

Exhibit Index. Exhibit 24 - Power of Attorney

	/s/ Todd Anderman, Attorney-in-Fact for Jason Shand Robins	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the reporting insider in Ocular Therapeutix (OCUL)'s latest Form 3?

The reporting insider is Jason Shand Robins, who serves as Interim CFO of Ocular Therapeutix, Inc. and is filing as a single reporting person.

How many Ocular Therapeutix (OCUL) common shares does the interim CFO beneficially own?

Interim CFO Jason Shand Robins beneficially owns 52,656 shares of common stock directly, which includes both vested shares and unvested restricted stock units.

What RSU awards are included in the interim CFO's Ocular Therapeutix (OCUL) holdings?

His holdings include 20,917 unvested RSUs from a grant of 31,375 RSUs on January 13, 2025 under the 2019 Inducement Stock Incentive Plan and 22,425 unvested RSUs from a grant on January 2, 2026 under the 2021 Stock Incentive Plan.

How do the RSUs for Ocular Therapeutix (OCUL) interim CFO vest?

Subject to continued service, each RSU grant vests over three years: 1/3 of the shares vests on the one-year anniversary of the grant date and an additional 1/3 vests at the end of each of the next two years.

What stock options does the Ocular Therapeutix (OCUL) interim CFO hold and at what prices?

He holds two stock option awards: one for 110,600 shares at an exercise price of $8.12 per share expiring on January 12, 2035, and another for 68,195 shares at $11.82 per share expiring on January 1, 2036, both held directly.

What are the vesting schedules of the Ocular Therapeutix (OCUL) interim CFO's stock options?

The option granted on January 13, 2025 vests over four years, with 25% vesting on January 13, 2026 and the remainder vesting in equal monthly installments over the next three years. The option granted on January 2, 2026 vests over four years with 1/48 of the shares vesting monthly starting one month after the grant date.